Evidence map›Paper›PMID 41622393›Full record

ArticleJournal of thrombosis and thrombolysis2026

The coagulation-inflammation axis in advanced cancer: associations with cardiovascular-thrombotic complications.

Charlotte Wagner, Fiona Bruns, Claudia Maletzki, Annabell Wolff, Moosheer Alammar, Anett Seifert, Ursula Kriesen, Karen Rischmüller, Sonja Oehmcke-Hecht, Christian Junghanss

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Charlotte WagnerDepartment of Internal Medicine, Clinic and Polyclinic for Hematology, Hemostaseology, Oncology, Stem Cell Therapy, and Palliative Medicine, Rostock University Medical Center, University of Rostock, Ernst-Heydemann-Str. 6, D-18057, Rostock, Germany. charlotte.wagner@med.uni-rostock.de.ORCID http://orcid.org/0009-0001-8269-1057
Fiona BrunsDepartment of Internal Medicine, Clinic and Polyclinic for Hematology, Hemostaseology, Oncology, Stem Cell Therapy, and Palliative Medicine, Rostock University Medical Center, University of Rostock, Ernst-Heydemann-Str. 6, D-18057, Rostock, Germany.
Claudia MaletzkiDepartment of Internal Medicine, Clinic and Polyclinic for Hematology, Hemostaseology, Oncology, Stem Cell Therapy, and Palliative Medicine, Rostock University Medical Center, University of Rostock, Ernst-Heydemann-Str. 6, D-18057, Rostock, Germany.
Annabell WolffDepartment of Internal Medicine, Clinic and Polyclinic for Hematology, Hemostaseology, Oncology, Stem Cell Therapy, and Palliative Medicine, Rostock University Medical Center, University of Rostock, Ernst-Heydemann-Str. 6, D-18057, Rostock, Germany.
Moosheer AlammarDepartment of Internal Medicine, Clinic and Polyclinic for Hematology, Hemostaseology, Oncology, Stem Cell Therapy, and Palliative Medicine, Rostock University Medical Center, University of Rostock, Ernst-Heydemann-Str. 6, D-18057, Rostock, Germany.
Anett SeifertDepartment of Internal Medicine, Clinic and Polyclinic for Hematology, Hemostaseology, Oncology, Stem Cell Therapy, and Palliative Medicine, Rostock University Medical Center, University of Rostock, Ernst-Heydemann-Str. 6, D-18057, Rostock, Germany.
Ursula KriesenDepartment of Internal Medicine, Clinic and Polyclinic for Hematology, Hemostaseology, Oncology, Stem Cell Therapy, and Palliative Medicine, Rostock University Medical Center, University of Rostock, Ernst-Heydemann-Str. 6, D-18057, Rostock, Germany.
Karen RischmüllerDepartment of Internal Medicine, Clinic and Polyclinic for Gastroenterology, Hepatology, and Nutritional Medicine, Rostock University Medical Center, University of Rostock, 18057, Rostock, Germany.
Sonja Oehmcke-HechtDepartment of Medical Interdisciplinary Studies, Institute of Medical Microbiology, Virology and Hygiene, Rostock University Medical Center, University of Rostock, 18057, Rostock, Germany.
Christian JunghanssDepartment of Internal Medicine, Clinic and Polyclinic for Hematology, Hemostaseology, Oncology, Stem Cell Therapy, and Palliative Medicine, Rostock University Medical Center, University of Rostock, Ernst-Heydemann-Str. 6, D-18057, Rostock, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular–thrombotic complications (CVTCs) are common in advanced malignancies and contribute substantially to morbidity and mortality. The relationships between inflammation, coagulation abnormalities, and extracellular vesicle (EV) profiles in palliative-stage disease remain insufficiently understood. In this exploratory cross-sectional study, clinical characteristics, coagulation parameters, inflammatory markers, and EV profiles were assessed at a single time point in 80 patients with advanced solid tumors receiving palliative care. Patients with a history of CVTCs were compared with those without. Patients with CVTCs showed higher levels of IL-6 and CRP, prolonged coagulation times, and lower activities of several coagulation factors, including FII, FVII, FX, FXII, and FXIII. Fibrinogen and d-dimer levels were elevated in the overall cohort and were higher in patients with CVTCs. Exploratory regression analyses indicated associations between lower FII activity, higher platelet counts, older age, and the presence of CVTCs. Cancer patients exhibited higher concentrations of small EV–like particles and shorter EV-associated clotting times compared with healthy donors; however, EV-related measures did not differ between patients with and without CVTCs. Palliative cancer patients demonstrate heterogeneous alterations in inflammatory and coagulation parameters, with more pronounced abnormalities in those with CVTCs. EV concentrations were elevated overall but did not distinguish between clinical subgroups. These findings are descriptive and hypothesis-generating, underscoring the need for longitudinal studies to clarify temporal relationships, potential mechanistic pathways, and the clinical relevance of coagulation and EV-associated alterations in advanced cancer.

Indexed as

Blood CoagulationCardiovascular DiseasesInflammationNeoplasmsThrombosisAgedBlood Coagulation FactorsCross-Sectional StudiesExtracellular VesiclesFemaleHumansMaleMiddle AgedPalliative CareBlood Coagulation FactorsAnticoagulationCardiovascular-thrombotic complicationsCoagulation dysregulationExtracellular vesiclesPalliative cancer

Identifiers

PMID41622393
PMCPMC13264542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.